Ipsen - Crunchbase Company Profile & Funding

Q: When was the last funding round for Ipsen?

Ipsen closed its last funding round on obfuscated from a Post-IPO Debt round.

Overview

Ipsen

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Events

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Ipsen

CB Rank

3115

Ipsen is a global specialty-driven biopharmaceutical company focused on innovation and specialty care.

Founded

obfuscation

Public

Post-IPO Debt

Boulogne-billancourt, Ile-de-France, France

1001-5000

www.ipsen.com

Biotechnology

Pharmaceutical

Product Research

Funding Rounds

Post-IPO Debt

OBF

obfuscation

Post-IPO Equity

OBF

obfuscation

Key People

Elisabeth Vey: Analytical Development Leader
Sandra Silvestri: EVP, Chief Medical Officer, Head of Global Medical Affairs, Patient Safety & Patient Affairs

Details

Legal Name

Ipsen S.A.

Operating Status

Active

Number of Exits

obfuscation

Stock Symbol

EPA:IPN

Company Type

For Profit

Founders

Henri Beaufour

About the Company

Ipsen is a global specialty-driven biopharmaceutical company focused on innovation and specialty care. Ipsen develops and commercializes innovative medicines in three key therapeutic areas: oncology, neuroscience, and rare disease. Its dedication to oncology is exemplified by its expanding portfolio of key therapies for prostate cancer,

neuroendocrine tumors, renal cell carcinoma and pancreatic cancer.

Phone Number

(331) 583-3500

Contact Email

contact.web@ipsen.com

Predictions & Insights

Growth Insight

See this Growth Insight

Ipsen is

Lorem

to be growing

Top Contributing Factors

Financial Growth

Products & Services

Cabometyx®

A treatment for advanced neuroendocrine tumors and certain cancers including kidney, liver, pancreas, thyroid, prostate, and breast cancers.

IQIRVO® (elafibranor)

An investigational oral treatment for rare liver diseases, including primary biliary cholangitis and primary sclerosing cholangitis.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Debt - Ipsen	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Ipsen	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Ipsen	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Ipsen	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Ipsen	—	obfuscated obfuscation	—	Post-IPO Debt

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Debt - Ipsen	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Ipsen	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Ipsen	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Ipsen	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Ipsen	—	obfuscated obfuscation	—	Post-IPO Debt

Investors

Investments

Investment Breakdown

Diversity Investments

Number of Investments

Number of Exits

obfuscation

Number of Acquisitions

See investment data for this company, with details on deal size, industry, stage, and more.

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	GENFIT	Yes	Post-IPO Equity - GENFIT	obfuscated obfuscation
obfuscated obfuscation	GENFIT	Yes	Post-IPO Equity - GENFIT	obfuscated obfuscation
obfuscated obfuscation	GENFIT	Yes	Post-IPO Equity - GENFIT	obfuscated obfuscation
obfuscated obfuscation	GENFIT	Yes	Post-IPO Equity - GENFIT	obfuscated obfuscation
obfuscated obfuscation	GENFIT	Yes	Post-IPO Equity - GENFIT	obfuscated obfuscation

Investment Breakdown

Number of Investments

Number of Exits

obfuscation

Number of Acquisitions

See investment data for this company, with details on deal size, industry, stage, and more.

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	GENFIT	Yes	Post-IPO Equity - GENFIT	obfuscated obfuscation
obfuscated obfuscation	GENFIT	Yes	Post-IPO Equity - GENFIT	obfuscated obfuscation
obfuscated obfuscation	GENFIT	Yes	Post-IPO Equity - GENFIT	obfuscated obfuscation
obfuscated obfuscation	GENFIT	Yes	Post-IPO Equity - GENFIT	obfuscated obfuscation
obfuscated obfuscation	GENFIT	Yes	Post-IPO Equity - GENFIT	obfuscated obfuscation

Diversity Investments

Number of Diversity Investments

Announced Date	Organization Name	Diversity Spotlight	Funding Round	Money Raised
obfuscated obfuscation	Rhythm Pharmaceuticals	Women Founded	Venture Round - Rhythm Pharmaceuticals	obfuscated obfuscation
obfuscated obfuscation	Motus Therapeutics	Women Founded	Series B - Motus Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Rhythm Pharmaceuticals	Women Founded	Series B - Rhythm Pharmaceuticals	obfuscated obfuscation
obfuscated obfuscation	Motus Therapeutics	Women Founded	Series B - Motus Therapeutics	obfuscated obfuscation

Market Intelligence

People

View Profiles & Contacts

Headcount

1001-5000

Employee Profiles

Board Members and Advisors

Contacts

2,682

Employee Profiles

Elisabeth Vey Analytical Development Leader
Sandra Silvestri EVP, Chief Medical Officer, Head of Global Medical Affairs, Patient Safety & Patient Affairs
Philippe Lopes-Fernandes Executive Vice President, Chief Business Officer, Member of the Executive Committee
Paul Murasko Head of Digital Customer Interaction for North America